Skip to main content

Table 4 Changes of TE scores (kPa) over time assessed by linear mixed effects models for patients treated with TDF vs. untreated

From: Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study

  Crude model   Adjusted for baseline age, gender, ethnicity
  Coefficient β (95% CI) p-value Coefficient β (95% CI) p-value
(Intercept) 5.088 (4.693, 5.483) < 0.001 4.586 (3.385, 5.787) < 0.001
Group 1.758 (0.977, 2.540) < 0.001 1.729 (0.926, 2.533) < 0.001
Time 0.006 (− 0.008, 0.020) 0.416 0.006 (− 0.008, 0.020) 0.421
Group x Time a −0.038 (− 0.065, − 0.011) 0.006 −0.040 (− 0.067, − 0.013) 0.004
  1. a x indicates the interaction between group and follow-up time. Group = {0,1}, where 0 indicates untreated, 1 indicates TDF. CI confidence interval; TDF Tenofovir disoproxil fumarate